Sponsor
CQDM
Program
Canada Europe Joint Funding Initiative
Description
Eligibility
Must include a strong collaboration between at least one research entity (academic or private) in Canada and at least one private entity in Germany.
Funding Availability
Maximum $380,000 EU for each applying SME in Germany and $500,000 for Canada. See details for RTOs in call for proposals.
Indirect Costs
40%
Special Notes
- A research agreement must be signed by all research entities involved in the project within 3 months after the funding confirmation.
- Intellectual property generated under this funding program will be managed according to the policies of the financial partners involved.
- A licence option will be granted to the CQDM industrial sponsors (currently Merck and Pfizer and their subsidiaries) for the use of the results for R&D purposes only. The main conditions of the end user license option will be negotiated before the beginning of the project and will take into account pre- existing IP as well as contribution from each party.
- CDQM industrial sponsors will have no rights to commercialize the IP resulting from the project or the pre-existing IP.
Deadlines
If College-level review is required, your College will communicate its earlier internal deadlines.
Type | Date | Notes |
---|---|---|
Internal Deadline | Please submit a copy of your full application along with a signed OR5 form to the Research Services email address at resserv@uoguelph.ca [1] | |
External Deadline | Candidates must submit their short common application form and full application form. |
How to Apply
Please see the letter of intent and proposal information and forms [2].
Each research proposal must:
- Include strong collaboration between at least one research entity (public or private) in Canada and at least one private entity in Germany. *Please note: In Germany, a private entity (SME) is mandatory to apply. Public and private non-profit research and technology organizations (RTOs) acting as cooperation partners for a SME are also eligible for ZIM-fnding. In Canada the participation of a private organization is highly encouraged and preferred, but not mandatory, Universities are eligible.
- Generate clear deliverables with immediate applications in the drug discovery and/or development process of new therapeutics.
- Be highly innovative with a strong and wide potential impact on biopharmaceutical research.